Skip to main content

Table 3 Response to alemtuzumab at 6 and 12 months

From: Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)

 

AAV (n = 12)

BD (n = 11)

Total (n = 23)

At 6 months in CR

4/12 (33.3%)

2/11 (18.2%)

6/23 (26.1%)

At 6 months in PR

5/12 (41.6%)

5/11 (45.5%)

10/23 (43.5%)

At 6 months CR or PR

9/12 (75%)

7/11 (63.6%)

16/23 (69.5%)

At 12 months in CR

5/12 (41.6%)

4/11 (36.4%)

9/23 (39.1%)

At 12 months in PR

0/12 (0%)

1/11 (9.1%)

1/23 (4.4%)

At 12 months CR or PR

5/12 (41.6%)

5/11 (45.5%)

10/23 (43.5%)

  1. CR complete response, PR partial response, AAV ANCA-associated vasculitis, BD Behçet’s disease